[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355824-105":59,"doc-detail-355824-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","integrative-transcriptomic-and-functional-analysis-of-pkmyt1-reveals-a-potential-therapeutic-target-in-chronic-lymphocytic-leukemia","Integrative Transcriptomic and Functional Analysis of PKMYT1 Reveals a Potential Therapeutic Target in Chronic Lymphocytic Leukemia","","Chronic lymphocytic leukemia (CLL) is clinically and molecularly heterogeneous. PKMYT1, a G2/M cell-cycle kinase, is implicated in tumor progression in several cancers, yet its function in CLL is unclear. PKMYT1 expression in primary CLL samples is heterogeneous and correlates with adverse cytogenetic and clinical features, including complex karyotype and elevated leukocyte counts. Transcriptomic profiling links high PKMYT1 expression to chromatin remodeling, DNA repair, and mitotic regulation, while PKMYT1 inhibition reduces MEC1 viability and induces apoptotic, inflammasome-associated, and necroptotic pathways.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrative-transcriptomic-and-functional-analysis-of-pkmyt1-reveals-a-potential-therapeutic-target-in-chronic-lymphocytic-leukemia/355824/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrative-transcriptomic-and-functional-analysis-of-pkmyt1-reveals-a-potential-therapeutic-target-in-chronic-lymphocytic-leukemia/355824.png","ImageObject",300,407,{"name":92,"@type":93},"Dipper","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main focus regarding PKMYT1 in CLL?","Question",{"text":112,"@type":113},"The study evaluates PKMYT1 expression in CLL, its association with cytogenetic and clinical features, and its functional relevance for cell survival.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What correlations were observed between PKMYT1 expression and disease features?",{"text":117,"@type":113},"PKMYT1 expression was heterogeneous and associated with adverse characteristics, including complex karyotype and higher leukocyte counts.",{"name":119,"@type":110,"acceptedAnswer":120},"How does PKMYT1 inhibition affect CLL cell viability and pathway activation?",{"text":121,"@type":113},"Pharmacological PKMYT1 inhibition significantly reduces cancer cell viability and is associated with upregulation of genes indicating apoptotic, inflammasome-associated, and necroptotic pathway activation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355824,1790169096,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Hematological Oncology   \nIntegrative Transcriptomic and Functional Analysis of PKMYT1 Reveals a Potential Therapeutic Target in Chronic Lymphocytic Leukemia  \nElizabete Cristina Iseke Bispo1 | Cláudia de Souza Lima Pontes1 | Jennifer Martins do Nascimento1 |  \nFábio Wilson de Lima Alves1 | Juliana Lott de Carvalho2 | Antônio Roberto Lucena‐Araujo3 | Felipe Saldanha‐Araujo1   \n1Laboratório de Hematologia e Células‐Tronco, Faculdade de Ciências da Saúde, Universidade de Brasília, Brasília, Distrito Federal, Brasil | 2Laboratório de Biociências, Faculdade de Medicina, Universidade de Brasília, Brasília, Distrito Federal, Brasil | 3Laboratório de Hematologia, Centro de Biociências, Universidade Federal de Pernambuco, Recife, Pernambuco, Brasil  \nCorrespondence: Felipe Saldanha‐Araujo ([felipearaujo@unb.br](felipearaujo@unb.br))  \nReceived: 16 March 2026 | Revised: 25 May 2026 | Accepted: 2 June 2026  \nKeywords: cell cycle regulation | chronic lymphocytic leukemia | complex karyotype | genomic instability | PKMYT1 | therapeutic target  \nABSTRACT  \nChronic lymphocytic leukemia (CLL) is a clinically and molecularly heterogeneous disease. PKMYT1, a G2/M cell cycle kinase, has been implicated in tumor progression in several cancers, but its role in CLL remains unclear. We evaluated PKMYT1 expression in primary CLL samples and analyzed associations with cytogenetic features and clinical parameters. PKMYT1 expression was heterogeneous and correlated with adverse features, including complex karyotype and elevated leukocyte counts. Comparative transcriptomic analyses between high‐ and low‐expression groups revealed enrichment of pathways related to chromatin remodeling, DNA repair, and mitotic regulation. In MEC1 cells, pharmacological PKMYT1 inhibition significantly reduced cancer cell viability. PCR analysis showed upregulation of TP53, CASP3, BAK, GSDMD, BCL2, CASP1, IL1β, RIPK1, and RIPK3, indicating activation of apoptotic, inflammasome‐associated, and necroptotic pathways. Collectively, these findings demonstrate that PKMYT1 is heterogeneously expressed in CLL, associated with adverse cytogenetic and clinical features, and critical for cell survival, highlighting its potential as a therapeutic target.  \n1 | Introduction  \nChronic lymphocytic leukemia (CLL) is a clonal malignancy of CD5+ B cells and represents the most common form of adult leukemia, particularly in aging populations worldwide. The clinical course of CLLis highly heterogeneous, with some patients remaining asymptomatic for years while others experience rapid disease progression, therapeutic resistance, and poor survival outcomes. This variability is largely influenced by underlying genomic alterations and disruptions in key regulatory pathways [1] .  \nItiswell established that genomic instability plays a central role in CLL pathogenesis and progression, driving the accumulation of  \nchromosomal aberrations and subclonal evolution. However, the molecular mechanisms that govern the maintenance genome integrity in CLL cells remain incompletely understood [2, 3] .  \nAmong the pathways involved in genomic surveillance, the DNA damage response (DDR) and cell cycle checkpoints are critical for preventing the propagation of damaged DNA. The kinases WEE1 and PKMYT1 act as negative regulators of CDK1 activity, enforcing the G2/M checkpoint to allow time for DNA repair. While WEE1 has been extensively studied in hematologic malignancies and is currently under clinical investigation as a therapeutic target in acute myeloid leukemia and lymphomas [4, 5], the functional relevance of PKMYT1 in these contexts remains poorly defined.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s) . Hematological Oncology published by John Wiley & Sons Ltd.  \nHematological Oncology, 2026; 44:e70208 1 of 9  \n[https://doi.org/1","cbCaidO2DouXlhXd","https://ap.wps.com/l/cbCaidO2DouXlhXd","pdf",2064247,"English","# Abstract\n## Introduction\n## Methods\n## Sample Collection\n## Sample Processing, Immunophenotyping, and Cytogenetic Characterization","[{\"question\":\"What is the main focus regarding PKMYT1 in CLL?\",\"answer\":\"The study evaluates PKMYT1 expression in CLL, its association with cytogenetic and clinical features, and its functional relevance for cell survival.\"},{\"question\":\"What correlations were observed between PKMYT1 expression and disease features?\",\"answer\":\"PKMYT1 expression was heterogeneous and associated with adverse characteristics, including complex karyotype and higher leukocyte counts.\"},{\"question\":\"How does PKMYT1 inhibition affect CLL cell viability and pathway activation?\",\"answer\":\"Pharmacological PKMYT1 inhibition significantly reduces cancer cell viability and is associated with upregulation of genes indicating apoptotic, inflammasome-associated, and necroptotic pathway activation.\"}]","Integrative Transcriptomic and Functional Analysis of PKMYT1 Reveals a Potential Therapeutic Target in Chronic Lymphocytic Leukemia | PDF",1790121218,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f37e3219f7c7ffe60b03cfc62704d1b.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b317208a1e2fada798dff11bdbed43f.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/452ef0356173177c077508b5c268c251.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bbf40bf985617f63343477d3425d4d13.webp",980,1287]